| Similar Articles |
|---|
 |
The Motley Fool
May 3, 2007
Billy Fisher |
Optimism for OSI With Tarceva sales growing across the board and the potential for new uses on the horizon, coupled with a shrewd divestiture of an unprofitable product, the general outlook for OSI appears to be quite favorable. Investors, take note.   |
The Motley Fool
May 5, 2005
Charly Travers |
OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech. |
The Motley Fool
February 27, 2007
Billy Fisher |
OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note. |
The Motley Fool
October 29, 2007
Billy Fisher |
Tarceva Sales Thrive at OSI The pharmaceutical's net revenue jumps 77%. Amazingly enough, there's still room for further growth at OSI. Investors, take note. |
The Motley Fool
January 5, 2005
Charly Travers |
AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
The Motley Fool
May 25, 2005
Tom Taulli |
Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note. |
The Motley Fool
November 6, 2006
Nathan Parmelee |
Outback Offer a Little Underdone OSI Restaurant Partners' offer to go private for $40 a share is reasonable, but not great. Here's why. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
The Motley Fool
December 30, 2009
Brian Orelli |
Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected. |
The Motley Fool
February 25, 2009
Brian Orelli |
Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer. |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
The Motley Fool
April 27, 2004
Alyce Lomax |
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux. |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
January 31, 2008
Brian Lawler |
Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention. |
The Motley Fool
February 7, 2008
Rich Smith |
I Spy OSI OSI, the airport security checkpoint equipment manufacturer, beats analyst estimates for the fifth consecutive quarter. |
The Motley Fool
January 26, 2009
Brian Orelli |
Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues. |
The Motley Fool
July 21, 2008
Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own. |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
The Motley Fool
August 28, 2008
Rich Smith |
OSI Sandbagged Its strong sales growth could soon be mired in quicksand, and rightfully so. |
The Motley Fool
November 21, 2008
Brian Orelli |
The Comeback of the Century? AstraZeneca is trying to revive Iressa. |
The Motley Fool
August 17, 2007
Brian Lawler |
The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
July 12, 2006
Stephen D. Simpson |
Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered. |
The Motley Fool
April 12, 2005
Brian Gorman |
Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently. |
